An observational study in Cerebrovascular Disorders, Vascular: Intracranial and Intimal Dissection, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-13.
Sponsored by Insel Gruppe AG, University Hospital Bern · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Stroke by Insel Gruppe AG, University Hospital Bern — 7 open to participants now, 7 under way, 1 of them phase 3. Stroke · Insel Gruppe AG, University Hospital Bern.
Among the 19 studies in Stroke by Insel Gruppe AG, University Hospital Bern, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2016, is one of 11 observational ones, and was the 9th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →7 of the 19 studies in Stroke by Insel Gruppe AG, University Hospital Bern are open now, in 12 countries. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–70
Insel Gruppe AG, University Hospital Bern · Sites in Belgium, Germany, New Zealand and 3 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Australia, Austria, Denmark and 5 more countries
Ages 6 mo–17 yrs
Insel Gruppe AG, University Hospital Bern · Sites in Austria, Germany, Switzerland
Ages 50+
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 156 across the 8 interventional studies, 447 across the 11 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
1 of the studies in Stroke by Insel Gruppe AG, University Hospital Bern that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02756091Insel Gruppe AG, University Hospital BernInternational Intracranial Dissection Study | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Stroke by Insel Gruppe AG, University Hospital Bern, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Cervicocerebral artery dissection is a major cause for stroke in young adults. While knowledge of cervical artery dissection (CeAD) has increased thanks to a number of high quality studies, knowledge on intracranial artery dissection (IAD) is limited. Due to treatment and publication bias little is known about the natural history of IAD. Overall, IAD is assumed to have a more severe course than CeAD, with a more ominous outcome in patients with subarachnoid hemorrhage (SAH). Furthermore, little information is available on the risk of recurrent IAD as well as on the risk of recurrent ischemic and haemorrhagic events in non-Asian patients. Radiological diagnosis of IAD can be challenging given the small size of intracranial arteries, and the subtle and non-specific radiological signs which tend to evolve over time. The optimal treatment of IAD is unknown. There are no randomised trials and only observational studies with relatively small sample sizes are available, thus providing a very low level of evidence.
Finding the factors that are decisive for outcome and recurrence after intracranial artery dissection is key to an improved management of this potentially severe disease predominantly affecting young patients. By using standardised protocols for diagnosis, imaging and follow-up, the investigators intend to obtain large representative patient samples in order to fill the gap of evidence.
Cervicocephalic artery dissection corresponds to a hematoma in the wall of a cervical or an intracranial artery and is an important cause of stroke in children and young and middle-aged adults. While extracranial cervical artery dissection (CeAD) has been extensively studied and described, less information is available on pure intracranial artery dissection (IAD) not involving the cervical portion of the artery. Early reports were based exclusively on autopsy series, hence biased towards the most severe cases. The incidence of IAD is unknown, but is probably lower than the incidence of symptomatic CeAD in populations of European origin. The proportion of IAD among all cervicocephalic dissections varies substantially between ethnic and age groups, and depending on study recruitment strategies and ascertainment methods. Indeed, recruitments through departments of neurology are biased towards CeAD and IAD presenting with local symptoms and/or ischaemic stroke while recruitments through departments of neurosurgery or interventional neuroradiology are biased towards IAD presenting with subarachnoid haemorrhage (SAH).Therefore, patients with IAD are managed not only by neurologists, but also by neurosurgeons, and interventional neuroradiologists, each having an incomplete picture of the disease.
The vast majority of reported series of IAD patients come from Asian countries and IAD affects the posterior circulation more frequently than the anterior circulation in these series. This contrasts with CeAD and saccular intracranial aneurysms, which most commonly affect the anterior circulation. Due to treatment and publication bias little is known about the natural history of IAD. Overall, IAD is assumed to have a more severe course than CeAD, with a more ominous outcome in patients with SAH IAD than in patients with non-SAH IAD. Furthermore, little information is available on the risk of recurrent IAD as well as risk for recurrent ischaemic and haemorrhagic events. Radiological diagnosis of IAD can be challenging given the small size of intracranial arteries, and the subtle and non-specific radiological signs which tend to evolve with time.
The optimal treatment of IAD is unknown. There are no randomised trials and only observational studies with relatively small sample sizes are available, thus providing a very low level of evidence. Patients with SAH IAD are usually treated by surgery or endovascular procedures because up to 40% of the patients experience re-bleeding within the first days after the event. Various surgical and endovascular treatment methods have been proposed for intracranial dissecting aneurysms. When patients are in poor clinical condition or treatment has an unacceptably high complication risk, it can be decided to withhold from surgical or endovascular treatment. In addition, Most non-SAH IAD patients have been treated medically, but the choice of antithrombotic therapy (anticoagulants or antiplatelet agents) has been evaluated neither in randomised trials nor in systematic reviews and meta-analyses of observational data. As a consequence, there is currently no consensus on optimal treatment of IAD.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
This study's planned enrollment of 500 is above the median of 150 across 1,971 observational studies indexed under Stroke.
Browse Stroke studies →Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
Compared within Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cerebrovascular Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients are recruited in a consecutive ongoing recruitment process in daily clinical practice.
Patients who are hospitalized in participant sites are screened by authorized study group members according to local daily practice. If the patient matches the selection criteria (inclusion and exclusion criteria)he/she is enrolled in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Modified Rankin Scale score (mRS score)
The mRS is a standardised valid measure to semi-quantify functional outcome after stroke.
Time frame: 180 days after diagnosis +/- 30 days
Recurrence of stroke
Time frame: 180 days after diagnosis
Recurrence of cervico- cerebral dissection
Time frame: 90 days, 180 days, 12 months
Recurrence of stroke
Time frame: 0-10 days, 90 days, 12 months after diagnosis
Change in Modified Rankin Scale score (mRS score) from before diagnosis to follow up
The mRS is a standardised valid measure to semi-quantify functional outcome after stroke.
Time frame: 0-10 days, 90 days, 12 months after diagnosis
Change in occupational status from before diagnosis to follow up
The patients' profession, workload (whether the patient is full time or part time working) and, if the patient is not working, the reason why he or she is not working (e.g. for medical reason) are assessed by patient interview according to local routine procedure.
Time frame: 0-10 days, 90 days, 180 days, 12 months after diagnosis
Mortality
Time frame: 0-10 days, 90 days, 180 days, 12 months after diagnosis
Increase or reduction in size (>50% local degree of stenosis) or disappearance of stenosis at 6 months (in patients with stenotic and occlusive dissection)
Assessed by radiological assessments according to local routine procedures.
Time frame: 180 days after diagnosis
Increase or reduction in size (> 20% maximal diameter) of aneurysms at 6 months (in patients with aneurysm)
Assessed by radiological assessments according to local routine procedures.
Time frame: 180 days after diagnosis
Personal and familiar risk factors for intracranial artery dissection
Assessment of personal and familiar risk factors according to local routine procedures (may differ according to local standard). Risk factors will be elicited by patient questionnaire or by questioning of patients' next of kin.
Time frame: 0-10 days after diagnosis
Laboratory parameters assessed by blood test
Assessment of laboratory findings according to local routine procedures (may differ according to local standard).
Time frame: 90 days, 180 days, 12 months
Radiological findings assessed by magnetic resonance imaging (MRI), magnetic resonance angiography, computed tomography (CT), computed tomography angiography, digital subtraction angiography or duplex sonography
Assessment of radiological findings according to local routine procedures (may differ according to local standard).
Time frame: 0-10 days, 90 days, 180 days, 12 months after diagnosis
Localization of intracranial artery dissection
Localization of intracranial artery dissection by imaging modalities according to local routine procedures (may differ according to local standard).
Time frame: 0-10 days after diagnosis
Demographic variables
Assessment of demographic variables according to local routine procedures (may differ according to local standard). Demographic variables will be elicited by patient questionnaire or by questioning of patients' next of kin.
Time frame: 0-10 days after diagnosis
The record gives a start of Aug 2016, a primary completion of Nov 2026 and a completion of Nov 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →